Our Pipeline and Progress
Developing first-in-class Nck modulators for autoimmune disease
Our first-in-class, novel mechanism holds broad potential to treat T cell mediated autoimmune diseases such as psoriasis, atopic dermatitis, psoriatic arthritis, ankylosing spondylitis, and many others, while simultaneously allowing the body to fight foreign pathogens.
Psoriasis
Psoriasis is an autoimmune disease affecting the skin. It causes a rash with itchy, scaly patches, most commonly on the knees, elbows, trunk, and scalp. Psoriasis is a long-term disease with no cure. It can be painful, interfere with sleep, and make it hard to concentrate. It is estimated that more than 7 million adults in the US have psoriasis today. AX-158 is an oral agent evaluated in patients with mild to moderate psoriasis, with encouraging Phase 2a results reported in early 2025.
-
- Press Releases
Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study
Cambridge, MA, January 22, 2025 – Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the… -
- Press Releases
Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158
Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158 -
- Press Releases
Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study
Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study Patient Enrollment Expected to…
Atopic dermatitis
Atopic dermatitis (atopic eczema) is a chronic, relapsing, and remitting inflammatory skin disease affecting one in 10 people in their lifetime. Repeated scratching triggers a self-perpetuating itch-scratch cycle, which can have a significant impact on the patient’s quality of life. We plan to initiate a Phase 2 clinical trial with AX-158 in patients with moderate to severe atopic dermatitis in 2025.
Autoimmune disease
We also plan to investigate the potential efficacy and safety of AX-158 in an additional autoimmune indication.
Additional programs
We are developing additional Nck modulator candidates. AX-194 is undergoing preclinical testing to enter Phase 1 clinical safety trials in healthy human volunteers in 2026.